Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin

a glycopeptide antibiotic and composition technology, applied in the direction of powder delivery, macromolecular non-active ingredients, dispersion delivery, etc., can solve the problems of excessive tissue accumulation, undesirable properties of glycopeptide antibiotics, sterically impractical and/or synthetically non-feasible,

Inactive Publication Date: 2002-06-20
CUMBERLAND PHARM INC
View PDF18 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when administered to a mammal, some glycopeptide antibiotics exhibit undesirable properties, such as excessive tissue accumulation, nephrotoxicity, histamine release (Red Man Syndrome) and vascular irritation.
As to any o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin

Examples

Experimental program
Comparison scheme
Effect test

formulation example b

[0190] This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this invention.

[0191] A frozen solution suitable for injection is prepared having the following composition:

2 Frozen Solution Active Compound 250 mg to 1000 mg Hydroxypropyl-.beta.-cyclodextrin 250 mg to 10 g Excipients - e.g., dextrose 0-50 g Water for Injection 10-100 mL The weight ratio of hydroxypropyl-.beta.-cyclo-dextrin to the active compound will typically be from about 1:1 to about 10:1.

[0192] Representative Procedure: Hydroxypropyl-p-cyclodextrin and excipients, if any, are dissolved in about 80% of the water for injection and the active compound is added and dissolved. The pH is adjusted with 1 M sodium hydroxide to 4.7.+-.0.3 and the volume is then adjusted to 95% of the final volume with water for injection. The pH is checked and adjusted, if necessary, and the volume is adjusted to the final volume with water for injection. The formulation is then ste...

formulation example c

[0193] This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this invention.

[0194] A lyophilized powder useful for preparing an injectable solution is prepared having the following composition:

3 Lyophilized Powder Active Compound 250 mg to 1000 mg Hydroxypropyl-.beta.-cyclodextrin 250 mg to 10 g Excipients - e.g., mannitol, 0-50 g sucrose and / or lactose Buffer agent - e.g., citrate 0-500 mg The weight ratio of hydroxypropyl-.beta.-cyclodextrin to the active compound will typically be from about 1:1 to about 10:1.

[0195] Representative Procedure: Hydroxypropyl-.beta.-cyclodextrin and excipients and / or buffering agents, if any, are dissolved in about 60% of the water for injection. The active compound is added and dissolved and the pH is adjusted with 1 M sodium hydroxide to 4.0-5.0 and the volume is adjusted to 95% of the final volume with water for injection. The pH is checked and adjusted, if necessary, and the volume is adj...

formulation example d

[0197] This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this invention.

[0198] A sterile powder useful for preparing an injectable solution is prepared having the following composition:

4 Sterile Powder Active Compound 250 mg to 1000 mg Hydroxypropyl-.beta.-cyclodextrin 250 mg to 10 g.sup.1 Excipients optional The weight ratio of hydroxypropyl-.beta.-cyclodextrin to the active will typically be from about 1:1 to about 10:1.

[0199] Representative Procedure: Hydroxypropyl-.beta.-cyclodextrin and the active compound (and any excipients) are dispersed into an appropriate sterile container and the container is sealed (optionally under partial vacuum or dry nitrogen), labeled and stored at room temperature or under refrigeration.

[0200] Administration of representative formulations C and D to a Patient

[0201] The pharmaceutical formulations described in formulation examples H and I above can be administered intravenously to a pati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Login to view more

Abstract

Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.

Description

PRIORITY OF INVENTION[0001] This application claims priority to United States Provisional Application No. 60 / 201,178, filed 02 May 2000; and to United States Provisional Applications Nos. 60 / 213,415; 60 / 213,410; 60 / 213,417; 60 / 213,146; 60 / 213,428, all filed 22 Jun. 2000; and to United States Provisional Application No. 60 / 226,727, filed 18 Aug. 2000, which applications are incorporated herein by reference in their entirety.[0002] 1. Field of the Invention[0003] This invention is directed to novel pharmaceutical compositions comprising a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic. This invention is also directed to methods for treating a bacterial disease in a mammal using such pharmaceutical compositions.[0004] 2. State of the Art[0005] Glycopeptide antibiotics and lipidated derivatives thereof are well-known in the art (see Glycopeptide Antibiotics, edited by R. Nagaraj an, Marcel Dekker, Inc. New York (1994)). These glycopeptide compounds are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00A61K9/00A61K9/02A61K9/14A61K9/19A61K9/20A61K9/48A61K47/06A61K47/12A61K47/26A61K47/40A61K47/48A61K51/08A61P31/04C07F9/38C07K1/113C07K9/00
CPCA61K9/0014C07K9/008A61K9/0095A61K9/02A61K9/19A61K9/2018A61K9/4858A61K31/724A61K38/14A61K47/06A61K47/12A61K47/26A61K47/40A61K47/48969B82Y5/00A61K9/0019A61K47/6951A61P31/00A61P31/04
Inventor JUDICE, J. KEVINSHAW, JENG-PYNGMU, YONGQICONNER, MICHAEL W.
Owner CUMBERLAND PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap